The sector posted a very strong third quarter performance driven by public biotech companies. (See the third quarter analysis on p. 1.) Since the emphasis of the forum is on early and established private companies as well as emerging public companies, the agenda has a heavy dose of business roundtables focused on early stage and creative financing and partnering strategies
By Peter Winter | BioWorld Insight | Monday, October 8, 2012
Public/other = Other financings of public companies, including loans, bridge financings, exercises of warrants, debt offerings, rights offerings, standard private placements, PIPE financings and institutional offerings of registered stock
Our capital markets are a critical source of funding for emerging companies and smaller public companies," said SEC Chairman Mary Schapiro, commenting on the formation of the committee...Another factor, described in a recently released paper by Grant Thornton and available for the meeting, argued that "adding back adequate economic incentives (through higher tick sizes, the minimum increment in which a stock or other security can trade) to make the aftermarket support of small public companies once
Our capital markets are a critical source of funding for emerging companies and smaller public companies," said SEC Chairman Mary Schapiro, commenting on the formation of the committee...Another factor, described in a recently released paper by Grant Thornton and available for the meeting, argued that "adding back adequate economic incentives (through higher tick sizes, the minimum increment in which a stock or other security can trade) to make the aftermarket support of small public companies once
By Peter Winter | BioWorld Insight | Monday, September 10, 2012
Public/other = Other financings of public companies, including loans, bridge financings, exercises of warrants, debt offerings, rights offerings, standard private placements, PIPE financings and institutional offerings of registered stock
In July, for example, the 212 biotechnology public companies tracked by the BioWorld Stock Report saw their collective share values increase by an average of over 5 percent
By Peter Winter | BioWorld Insight | Monday, August 20, 2012
Public/other = Other financings of public companies, including loans, bridge financings, exercises of warrants, debt offerings, rights offerings, standard private placements, PIPE financings and institutional offerings of registered stock
That figure is in line with an internal analysis that showed if Vitae were to go public, the cost of complying with SOX Section 404(b), which requires an annual external attestation of a public company's internal controls, would be about $1 million each year – plus a steep learning curve and corresponding costs, Hatfield said...6161, which was recently introduced in the House to update the SEC filing status classifications for public companies
By Mari Serebrov | BioWorld Today | Monday, July 30, 2012
Public/other = Other financings of public companies, including loans, bridge financings, exercises of warrants, debt offerings, rights offerings, standard private placements, PIPE financings and institutional offerings of registered stock
Private companies felt the pain significantly more than public companies: The total amount raised by private companies plummeted about 33 percent in 2012 compared to the comparable period last year...The total amount raised by public companies has dropped 20 percent so far this year
By Peter Winter | BioWorld Insight | Monday, June 18, 2012
Public/other = Other financings of public companies, including loans, bridge financings, exercises of warrants, debt offerings, rights offerings, standard private placements, PIPE financings and institutional offerings of registered stock
Editor's note: BioWorld will host a webinar June 12, 2012 on "Getting the JOBS Done Part I: How Private Life Sciences Firms Can Leverage the JOBS Act to Go Public by Traditional and Alternative Paths and Thrive as a Public Company
By Mari Serebrov | BioWorld Insight | Monday, June 4, 2012
While it's straightforward to crunch the data for public companies that have to report their finances, it's not possible to do the same for biotech start-ups
By Brian Orelli | BioWorld Today | Thursday, May 24, 2012
The sector posted a very strong third quarter performance driven by public biotech companies. (See the third quarter analysis on p. 1.) Since the emphasis of the forum is on early and established private companies as well as emerging public companies, the agenda has a heavy dose of business roundtables focused on early stage and creative financing and partnering strategies